U.S. Congressman Handling Science and Health Budget Purchases Stocks in Diagnostic Giants

U.S. Representative April McClain Delaney (D) disclosed on February 2 that she purchased common shares of clinical laboratory giant Labcorp Holdings Inc. (NASDAQ: LH) valued between $1,001 and $15,000 (roughly 1.3 million to 20 million South Korean won) on January 28. Serving on both the House Science, Space, and Technology Committee and the Agriculture Committee—where she oversees research and innovation funding as well as rural health policy—the lawmaker’s investment in a key healthcare stock has drawn attention over potential conflicts of interest.

Labcorp Holdings Inc. is a global diagnostics and laboratory services provider conducting more than 700 million tests annually across nearly 100 countries. The company relies heavily on demand from pharmaceutical firms developing biologics and from hospitals and clinics for routine and specialized testing. Labcorp has supported over 75% of new drug and therapy approvals in the U.S. in 2024, cementing its role as a core player in biotech and pharmaceutical research infrastructure. In 2025, its net profit margin jumped to 6.2%, reflecting a marked improvement in profitability.

Labcorp’s share price rose to a 52-week high of around $289 in October 2025 and closed at $276.16 on February 4—up more than 1% from the previous day—marking a second consecutive day of gains. With the next quarterly earnings report due February 17, the stock has climbed nearly 30% over the past year, driven by dividend increases, robust biopharma testing demand, and multiple analyst price-target upgrades.

Prior to Congress, McClain Delaney led broadband deployment and digital equity policy at the Commerce Department’s National Telecommunications and Information Administration. In the House, she has championed federal funding to protect NIH, Medicaid, and SNAP budgets, focusing on healthcare access for rural and low-income communities. Most recently, she joined a bipartisan effort to introduce the Women’s Health Insurance Act, which would expand coverage for breast reconstruction surgery for cancer survivors.

Her policy priorities—expanding diagnostic testing demand and insurance coverage—directly affect the growth prospects of companies like Labcorp. That overlap has fueled debate over whether a member of Congress who oversees related budgets and regulations should hold individual stocks in the same industry.

Under current rules, McClain Delaney’s disclosure satisfies legal requirements. Yet, given her role in shaping health appropriations and access legislation, the transaction carries political risk. Critics may question whether her private financial interests could sway her votes on matters involving federal research funding, Medicaid coverage, and public health programs. As lawmakers on and off Capitol Hill continue pushing for a ban on members owning individual stocks, this purchase is likely to intensify calls for stricter rules governing congressional investments in healthcare and science.